艾克美制药
ALKS
41.22
+1.12
+2.79%
艾克美制药
US · ALKS
#1780 按市值排名
上市于 1970
41.22
+1.12
+2.79%
实时 - 追踪5344个代码 - 心跳于187秒前
· 2026-10-16 19:53
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了2家。
- 机构持股总比例下降了0.2个百分点。
机构持股
- 机构持股比例
- 108.88% -0.25pp
- 机构数量
- 509 -2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund72.64%
Hedge Fund25.37%
VC/PE Fund4.23%
Public Company2.36%
Individual/Insider1.49%
Government Pension Fund1.37%
Sovereign Wealth Fund1.29%
Private Company0.80%
Insurance Company0.65%
主要股东 截至 2026-06-30
BlackRock
17.43% · 29.24M 股
Baker Bros. Advisors LP
5.97% · 10.01M 股
Vanguard Portfolio Management, LLC
5.66% · 9.49M 股
State Street Global Advisors
5.46% · 9.16M 股
Vanguard Capital Management, LLC
5.18% · 8.69M 股
T. Rowe Price Group, Inc.
4.67% · 7.83M 股
Renaissance Technologies Corp.
3.85% · 6.46M 股
Geode Capital Management, LLC
2.67% · 4.48M 股
Dimensional Fund Advisors
2.50% · 4.19M 股
Deep Track Capital, LP
2.38% · 4.00M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 25次买入 · 25次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Richard Pops | Chairperson & CEO | 0.82% |
| Blair Jackson | Chief Operating Officer | 0.14% |
| David Gaffin | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | 0.13% |
| David Daglio | Independent Director | 0.06% |
| Shane Cooke | Director | 0.06% |
| Christian Nichols | Chief Commercial Officer | 0.06% |
| Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | 0.04% |
| Brian McKeon | Independent Director | 0.03% |
| Nancy Snyderman | Independent Director | 0.02% |
| Frank Wilson | Independent Director | 0.02% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-10-01 | David Gaffin | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | Automatic Disposition | -2,034 | $41.03 |
| 2026-09-02 | David Gaffin | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | Automatic Disposition | -2,034 | $48.01 |
| 2026-08-31 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Automatic Disposition | -4,000 | $46.99 |
| 2026-08-31 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $24.59–46.99 |
| 2026-08-16 | Christian Nichols | Chief Commercial Officer | Automatic Disposition | -7,576 | $49.19–49.65 |
| 2026-08-04 | Blair Jackson | Chief Operating Officer | Other Derivative Acquisition | +217,534 | $49.61 |
| 2026-08-02 | Nancy Snyderman | Independent Director | Derivative Exercise and Sale | -44,472 | $46.72–50.35 |
| 2026-08-02 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Automatic Disposition | -4,000 | $48.58 |
| 2026-08-02 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $19.34–48.58 |
| 2026-08-02 | David Gaffin | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | Automatic Disposition | -2,034 | $48.58 |
| 2026-07-05 | David Gaffin | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | Automatic Disposition | -2,034 | $54.03 |
| 2026-06-30 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Automatic Disposition | -4,000 | $51.46–52.13 |
| 2026-06-30 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $19.34–51.46 |
| 2026-06-11 | Christopher I. Wright | Independent Director | Automatic Disposition | -2,000 | $45.10 |
| 2026-06-03 | David Gaffin | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | Automatic Disposition | -2,034 | $43.05 |
| 2026-05-31 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Automatic Disposition | -4,000 | $41.67 |
| 2026-05-31 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $19.34–41.67 |
| 2026-05-28 | Samuel Parisi | Interim Principal Accounting Officer & VP of Finance | Derivative Exercise and Sale | -16,217 | $19.34–42.36 |
| 2026-05-20 | Brian McKeon | Independent Director | Derivative Exercise and Sale | -1,475 | $36.95 |
| 2026-05-20 | Brian McKeon | Independent Director | Derivative Exercise and Retained | +4,667 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:53:58 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
艾克美制药 讨论区 0 条评论